MedTrace Logo

Impact of Increasing Levothyroxine Dose in Ramadan for UAE Patients With Hypothyroidism

NCT06135948 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 103

Last updated 2023-11-18

No results posted yet for this study

Summary

The study aims to compare the mean change in Thyroid Stimulating Hormone (TSH) levels among patients with hypothyroidism treated with an increased dose of L-thyroxine (treatment group) versus standard/regular dose of L-thyroxine (control group) during the month of Ramadan.

Conditions

  • L-thyroxine

Interventions

DRUG

Extra dose of L-thyroxine, 25 mcg during Ramadan

Extra dose of L-thyroxine, 25 mcg during the month of Ramadan

Sponsors & Collaborators

  • University of Sharjah

    collaborator OTHER

  • Emirates Health Services (EHS)

    lead OTHER_GOV

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-03-15
Primary Completion
2022-06-15
Completion
2022-06-15

Countries

  • United Arab Emirates

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06135948 on ClinicalTrials.gov